Provided by Tiger Fintech (Singapore) Pte. Ltd.

Astria Therapeutics Inc

5.70
-0.0200-0.35%
Volume:37.40K
Turnover:212.17K
Market Cap:321.68M
PE:-3.04
High:5.74
Open:5.72
Low:5.58
Close:5.72
Loading ...

Sector Update: Health Care Stocks Lean Lower Premarket Friday

MT Newswires Live
·
13 Jun

Astria announces initial results from ALPHA-SOLAR target enrollment group

TIPRANKS
·
13 Jun

Astria Therapeutics Announces Positive Results from ALPHA-SOLAR Trial, Highlighting Navenibart's Potential as a Market-Leading Treatment for Hereditary Angioedema

Reuters
·
13 Jun

Astria Therapeutics Inc - Navenibart Well-Tolerated With Favorable Safety Profile

THOMSON REUTERS
·
13 Jun

Astria Therapeutics Announces Positive Initial Results From the Alpha-Solar Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

THOMSON REUTERS
·
13 Jun

Astria Therapeutics Inc - Q3m Arm Shows 95% Mean Monthly Attack-Rate Reduction

THOMSON REUTERS
·
13 Jun

Astria Therapeutics Inc: Phase 3 Alpha-Orbit Trial Underway and Enrolling Patients

THOMSON REUTERS
·
13 Jun

Astria Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
13 Jun

BRIEF-Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
04 Jun

Astria Therapeutics Announces New Stock Option Grants as Part of 2022 Inducement Stock Incentive Plan

Reuters
·
04 Jun

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Jun

Astria Therapeutics CEO to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Reuters
·
28 May

Astria Therapeutics Inc. to Present at C1 Inhibitor Deficiency and Angioedema Workshop in Budapest

Reuters
·
23 May

Astria Therapeutics to Present at Eastern Allergy Conference on Hereditary Angioedema Trial Results

Reuters
·
22 May

Astria Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
16 May

Astria Therapeutics Price Target Maintained With a $47.00/Share by Cantor Fitzgerald

Dow Jones
·
14 May

Astria Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview

Reuters
·
14 May

Astria Therapeutics Shares Rise Following Update on In-Development Drugs

Dow Jones
·
14 May

BRIEF-Astria Therapeutics Q1 Operating Expenses USD 36.995 Million

Reuters
·
14 May

Astria Therapeutics Reports Q1 2025 Financial Results: Net Cash Used in Operations Increases to $34 Million

Reuters
·
14 May